Navigation Links
Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
Date:2/11/2011

SAN DIEGO, Feb. 11, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the pricing of a previously announced underwritten public offering of 6,000,000 shares of its common stock, offered at a price to the public of $11.25 per share. The gross proceeds to Optimer from this offering are expected to be $67.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Optimer.  The offering is expected to close on or about February 16, 2011, subject to customary closing conditions. Optimer has also granted the underwriters a 30-day option to purchase at the public offering price up to an additional 900,000 shares of its common stock to cover overallotments, if any.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Jefferies & Company, Inc. is acting as the sole book-running manager for the offering. Baird, Canaccord Genuity Inc., JMP Securities, Needham & Company, LLC, and ThinkEquity LLC are acting as co-managers for the offering.  

Optimer anticipates using the net proceeds from the offering to prepare for the potential commercial launch of fidaxomicin in the United States, if approved, as well as for research and development activities, potential in-licenses or acquisitions, working capital and other general corporate purposes.

A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission (SEC) and is effective. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtain
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013 /PRNewswire-iReach/ -- Specific Technologies, today announced ... demonstrating detection of pathogenic bacteria, including potential bioterrorism ... Bacillus anthracis which feature on the ... potential bio-threats. This seminal study, conducted in collaboration ... Salisbury (DSTL), United ...
(Date:5/20/2013)... Md. , May 20, 2013  TRACE International ... 2012 , finding that prosecutions against individuals and ... downward last year. The GER 2012 is ... assesses international anti-bribery enforcement trends. "Although the ... enforcement of bribery laws remained a priority," said ...
(Date:5/20/2013)... Calif. , May 20, 2013 A ... for use both in space and on Earth was ... The technology assures high quality, secure ... and low-power ultrasound units, like those used in hospitals ... already the diagnostic imaging solution of choice for human ...
Breaking Medicine Technology:Specific Technologies Detects and Identifies Potential Bioterrorism Pathogenic Bacteria 2TRACE Releases 2012 Global Enforcement Report 2TRACE Releases 2012 Global Enforcement Report 3Wyle Aided System Gets Named to Space Technology Hall of Fame 2Wyle Aided System Gets Named to Space Technology Hall of Fame 3
(Date:5/20/2013)... Lansing, MI (PRWEB) May 20, ... Michigan Lupus Foundation will be ... meeting in Lansing on June ... Monday, June 10th, 6:30 p.m. ... Professional Building (Across from Sparrow ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 According to ... expenses associated with medical malpractice amount to approximately $3.6 ... the Institute for Healthcare Improvement estimated that there 15 ... Statistics like these suggest that everyone who receives any ... basics of medical malpractice. Merriam-Webster defines malpractice as ...
(Date:5/20/2013)... 20, 2013 Co-founder of Atlanta ... a keynote speaker at the 5th International INVEST Domaining ... conference brings together company representatives and independent individuals from ... Internet marketing and investments. , The 2013 conference will ... Hotel México from May 20 to 21. A networking ...
(Date:5/20/2013)... 2013 Osborn’s Brain: Imaging, Pathology, ... G. Osborn’s 1993 award winning book Diagnostic Neuroradiology (a.k.a. ... bestselling neuroradiology texts. , In this highly anticipated ... make complex topics visually appealing and easy to understand. ... together with spectacular pathology examples, relevant anatomy, and the ...
(Date:5/20/2013)... 20, 2013 The Muscular Dystrophy ... leaders behind bars for good at an Executive Lock-Up ... at 9 a.m. , More than 100 “jailbirds” ... to benefit individuals and families affected by muscle disease. ... officials, local celebrities, realtors, doctors, attorneys, bankers, and members ...
Breaking Medicine News(10 mins):Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2Health News:Osborn’s Brain from Amirsys Publishing Receives Doody’s Top Honors 2Health News:MDA to Put Fort Lauderdale Community Leaders Behind Bars for Good 2
... after a mastectomy does not reduce the long-term survival of ... had a better chance of survival than those who did ... may boost the morale and self-esteem of the patient, which ... implants could stimulate the immune system and reduce blood flow ...
... successfully treat everything from breast to prostate cancer.// For the ... pancreatic cancer were involved , 42 percent had their tumors ... say , it turns off one of the switches within ... there’s much less side effects because it targets the cancer, ...
... more intense physical activity can help maintain cognitive skills ... // a new study. For the study researchers reviewed ... from the Finland, Italy, and Netherlands Elderly (FINE) study. ... participants was measured and cognitive function was evaluated starting ...
... study finds Alzheimer’s patients lose the ability to do ... ,Researchers conducted a study to look at the association ... 20 patients with Alzheimer’s disease. Eleven of the patients ... moderate Alzheimer’s disease. The study also included 23 healthy ...
... association between the level of sex hormones and an increased ... female hormones estrogen and progesterone play a key role in ... the cells, receiving and interpreting messages sent by the hormones. ... well as some breast cancer cells. Previous research has shown ...
... a new compound known as SP-4-84 could improve chemotherapy ... as cisplatin and camptothecin . ,Study results showed ... 75-times more effective. The compound sensitizes cancer cells to ... the damage caused by chemotherapeutic drugs. However, this was ...
Cached Medicine News:
... CELL-DYN 1700 was developed to address ... environment. Ease of use, low maintenance, ... high reliability are features expected in ... have made fast access to results, ...
... The OSOM Ultra Strep A Test ... Label Technology (DLT)**. DLT uses antibody labeled ... in the test device. DLT allows greater ... without sacrificing specificity. In the test procedure, ...
... The InstaCheck® Menopause Predictor Test is an ... of FSH in urine. Changes in FSH ... the symptoms associated with stages of menopause. ... to obtain a visual, qualitative result and ...
... a wealth of benefits to healthcare professionals and ... measure a complete lipid profile and glucose, ALT, ... in 5 minutes per test cassette (6 minutes ... demo, click here ., ,The accuracy, speed ...
Medicine Products: